What Arkea Bio does

Arkea Bio (legal entity ArkeaBio Corp.) is a U.S.-based agricultural bioscience company founded in 2022 and headquartered in Charlestown, Massachusetts. The company is developing a first-of-its-kind methane-reducing vaccine for cattle that stimulates the animal's immune system to produce antibodies against methane-producing microbes in the rumen, reducing enteric emissions without disrupting digestion or affecting meat or milk quality. Early trials have demonstrated 10-15% methane reduction with a stated pathway to greater than 40%, and the technology is positioned as non-GMO, organic-compatible, and uniquely scalable to the roughly 80% of the world's 1.2 billion cattle that are raised on pasture where feed-additive solutions cannot reach.

Arkea Bio is a single-product company in the pre-revenue stage, with commercialization planned to begin via farmer pilot programs in 2026-2027 ahead of a commercial launch before 2030. The company plans to monetize through vaccine sales to farmers and ranchers, potentially bundled with carbon-credit programs, payments for verified emissions reductions, and premium pricing for low-carbon beef and dairy in eco-conscious markets. Its target customer segments span farmers and ranchers, governments and policymakers, food producers and consumer brands (for Scope 3 emissions reductions), and end consumers of sustainable animal protein.

The business is venture-backed, with $40+ million raised across a $12 million seed (December 2022), a $26.5 million Series A (May 2024), and a $7 million Series A1 (September 2025), with Breakthrough Energy Ventures leading every round and AgriZeroNZ co-leading the most recent. The go-to-market motion is enterprise B2B, leveraging existing animal vaccine manufacturing and agricultural distribution infrastructure, and the company cites an addressable market estimated at more than $15 billion for cattle methane reduction. Strategic supporters include Fonterra, whose Chief Science & Technology Officer has publicly endorsed the technology's potential as a climate breakthrough.

Name

Arkea Bio

Legal name

ArkeaBio Corp.

Website

https://arkeabio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Arkea Bio is a U.S. agricultural bioscience company developing a first-of-its-kind vaccine that reduces methane emissions from cattle by stimulating antibodies against rumen microbes, serving farmers, food producers, governments, and consumers ahead of a pre-2030 commercial launch.

Ownership category

akta.pro rank

Product category

Livestock Methane-Reduction Vaccine

NAICS

Support Activities for Animal Production (11521)

SIC

Agricultural Services (700)

akta.pro primary industry

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Veterinary Vaccines (HLAIAEAH), Vaccination & Immunization Programs (Herd/Flock Health Protocols) (AFACALAA)

Keywords

• Methane vaccine
• Livestock emissions
• Agricultural biotechnology
• Cattle vaccine
• Enteric methane reduction

Headquarters

HQ city

Charlestown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Methane-Reducing Vaccine Sales: Pre-revenue company developing a vaccine to reduce livestock methane emissions. The company plans to generate revenue through vaccine sales to farmers, potentially bundled with carbon credit programs. Revenue will also come from payments for emissions reductions and premium pricing in sustainable meat and dairy markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Arkea Bio is developing a first-of-its-kind methane-reducing vaccine for cattle that triggers the animal's immune system to generate antibodies against methane-producing microbes in the rumen, lowering enteric methane emissions without disrupting digestion or harming the animal. The vaccine is positioned as a scalable, non-GMO, organic-compatible alternative to feed additives, designed to integrate with routine veterinary care and existing farm practices for commercial deployment ahead of 2030.

Product overview

Arkea Bio is a single-product company pioneering the development of a methane-reducing vaccine for cattle. Their core offering is a first-of-its-kind immunological solution that targets methane-producing microbes in the rumen of cattle, activating a natural immune response to reduce emissions without disrupting digestion. The company is advancing from current animal studies toward expanded field programs in 2026-2027, with commercial launch targeted before 2030.

Differentiator

Problem solved

Functional benefit

Products and services

• Methane-Reducing Vaccine for Cattle A first-of-its-kind vaccine that stimulates cattle immune systems to produce antibodies targeting methane-producing microbes in the rumen, reducing enteric methane emissions without disrupting digestion or affecting meat or milk quality. The vaccine is positioned as scalable to all the world's 1.2 billion cattle, cost-effective at under $100 per ton of emissions reduction, and compatible with organic farming.

Quantifiable outcome

• 10-15% methane reduction in early trials, with potential to reach >40% as formulation optimizations continue
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mootral: Mootral develops a garlic-and-citrus feed additive that reduces enteric methane emissions from cattle. It targets the same problem as ArkeaBio — lowering methane from beef and dairy herds — but uses a feed-based mechanism rather than an immunological vaccine, making it a directly comparable alternative solution.
• CH4 Global: CH4 Global commercializes Asparagopsis-based seaweed feed supplements to reduce enteric methane in cattle and sheep. Like ArkeaBio, it is pursuing large-scale methane abatement for livestock, positioning it as a directly competing approach to the same farmer and food-producer customers.
• Symbrosia: Symbrosia produces an Asparagopsis seaweed feed additive (SeaGraze) targeting enteric methane reduction in dairy and beef cattle. It is a direct competitor to ArkeaBio's vaccine in the livestock methane-reduction category, aimed at the same enterprise customers and emissions outcome.
• Blue Ocean Barns: Blue Ocean Barns develops Asparagopsis-based feed supplements for ruminants to cut enteric methane. It is directly comparable to ArkeaBio as an emerging methane-mitigation solution targeting dairy and beef producers and the carbon-credit value chain.
• Zelp: Zelp has developed a wearable methane-capturing mask/halter for cattle that oxidizes eructed methane. It addresses the same core problem as ArkeaBio — reducing cattle methane — but through a hardware/device solution, making it a directly comparable alternative for the same dairy and beef customers.
• Rumin8: Rumin8 develops seaweed and red-algae derived feed supplements to reduce enteric methane in cattle. It is a direct peer to ArkeaBio in the livestock methane-reduction space, pursuing the same enterprise customers (farmers, food brands, governments) with a feed-additive alternative to vaccines.
• Impetus Agriculture: Impetus Agriculture is developing a feed-additive product targeting enteric methane emissions in cattle. It is a directly comparable emerging player addressing the same problem and customer base as ArkeaBio, with a different (feed-based) delivery mechanism.

Broad incumbents

• dsm-firmenich: dsm-firmenich has commercialized Bovaer (3-NOP), a feed additive that reduces enteric methane in dairy cattle and is being rolled out with partners globally. As a major animal nutrition and health incumbent, it competes with ArkeaBio's vaccine in the same methane-reduction category but with established scale, regulatory approvals, and global distribution.
• Elanco Animal Health: Elanco is a large animal health company that has partnered with dsm-firmenich to commercialize Bovaer for the US market and offers a broad portfolio of livestock products. It competes with ArkeaBio in the methane-reduction space while bringing established veterinary sales channels, manufacturing, and regulatory expertise to the category.
• Alltech: Alltech is a global animal nutrition and health company with a broad portfolio including methane-mitigation feed technologies (e.g., Yea-Sacc, Egalis). It is a broad incumbent that overlaps with ArkeaBio's mission of reducing livestock emissions and competes for the same farmer and food-produyer customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

• Xx.com/arkeabio
• Facebookfacebook.com/arkeabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arkea Bio